Novartis Phase III APPOINT-PNH trial shows investigational
Data at EBMT show primary endpoint met – estimated* 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2...
Source: globenewswire.com
Page 11 - Reference Center News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Reference Center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Reference Center Today - Breaking & Trending Today
Novartis Pharma AG: Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients
Data at EBMT show primary endpoint met - estimated* 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2 g/dL or more hemoglobin-level increase from baseline
Source: finanznachrichten.de
Trial data released for potentially "practice-changing" PNH medicine
Iptacopan achieved "improvement of anaemia never seen before with anti-C5s” in PNH, showed Novartis data presented at 2023 EBMT.
Source: europeanpharmaceuticalreview.com
Iptacopan Meets Primary End Point of APPOINT-PNH Trial in Paroxysmal Nocturnal Hemoglobinuria
Iptacopan elicited improved hemoglobin levels measuring at least 2 g/dL higher vs baseline, leading to transfusion independence after 24 weeks in approximately 92.2% of patients with complement inhibitor–naïve paroxysmal nocturnal hemoglobinuria.
Source: onclive.com
Lufax : Supplemental and Updated Disclosures - Form 6-K
Lufax Holding Ltd Supplemental and Updated Disclosures Lufax Holding Ltd has published a listing document with the Stock Exchange of Hong Kong Limited ,... | April 11, 2023
Source: marketscreener.com